Abstract
Inflammation long has been recognized as a hallmark of atherosclerotic lesions, but more recently attention has focused on chronic low-level elevations of specific plasma inflammatory proteins such as C-reactive protein (CRP) and serum amyloid A (SAA), which may not only represent markers of atherosclerosis risk but also participate directly in atherogenesis. This article briefly reviews evidence for and against potential roles of CRP as an atherosclerosis risk marker and in atherogenesis. The remainder of the article focuses on SAA, an inflammatory protein that is carried on, and may fundamentally alter the function of, high-density lipoprotein. Data are reviewed regarding the regulation of SAA by dietary cholesterol, obesity, and insulin resistance, and its potential role as an atherosclerosis mediator. Lying at the intersection of inflammation, dyslipidemia, obesity, and insulin resistance, SAA may play a key role in regulating the contributions of these processes to atherogenesis.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801–809.
Ross R: Mechanisms of disease. Atherosclerosis—an inflammatory disease. N Engl J Med 1999, 340:115–126.
Malle E, De Beer FC: Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest 1996, 26:427–435.
Chang MK, Binder CJ, Torzewski M, Witztum JL: C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A 2002, 99:13043–13048.
De Beer FC, Soutar AK, Baltz ML, et al.: Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. J Exp Med 1982, 156:230–242.
Zwaka TP, Hombach V, Torzewski J: C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001, 103:1194–1197.
Ridker PM, Cushman M, Stampfer MJ, et al.: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973–979.
Kuller LH, Tracy RP, Shaten J, Meilahn EN: Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996, 144:537–547.
Koenig W, Sund M, Frohlich M, et al.: C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999, 99:237–242.
Ridker PM, Rifai N, Rose L, et al.: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347:1557–1565.
Visser M, Bouter LM, McQuillan GM, et al.: Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999, 282:2131–2135.
O’Brien KD, Brehm BJ, Seeley RJ, et al.: Diet-induced weight loss is associated with decreases in plasma serum amyloid A and C-reactive protein independent of dietary macronutrient composition in obese subjects. J Clin Endocrinol Metab 2005, In press.
Tannock LR, O’Brien KD, Knopp RH, et al.: Cholesterol feeding increases C-reactive protein and serum amyloid A levels in lean insulin-sensitive subjects. Circulation 2005, 111:3058–3062.
Festa A, D’Agostino R, Howard G, et al.: Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000, 102:42–47.
McLaughlin T, Abbasi F, Lamendola C, et al.: Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 2002, 106:2908–2912.
Leinonen E, Hurt-Camejo E, Wiklund O, et al.: Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis 2003, 166:387–394.
Weiss R, Dziura J, Burgert TS, et al.: Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004, 350:2362–2374.
Fredrikson GN, Hedblad B, Nilsson JA, et al.: Association between diet, lifestyle, metabolic cardiovascular risk factors, and plasma C-reactive protein levels. Metabolism 2004, 53:1436–1442.
Redberg RF, Rifai N, Gee L, Ridker PM: Lack of association of C-reactive protein and coronary calcium by electron beam computed tomography in postmenopausal women: implications for coronary artery disease screening. J Am Coll Cardiol 2000, 36:39–43.
Hunt ME, O’Malley PG, Vernalis MN, et al.: C-reactive protein is not associated with the presence or extent of calcified subclinical atherosclerosis. Am Heart J 2001, 141:206–210.
Johnson BD, Kip KE, Marroquin OC, et al.: Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women—The National Heart, Lung, and Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation (WISE). Circulation 2004, 109:726–732.
Ridker PM, Cannon CP, Morrow D, et al.: C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005, 352:20–28.
Nissen SE, Tuzcu EM, Schoenhagen P, et al.: Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005, 352:29–38.
Yusuf S, Hawken S, Ounpuu S, et al.: Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937–952.
Danesh J, Wheeler JG, Hirschfield GM, et al.: C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350:1387–1397.
Pearson TA, Mensah GA, Alexander RW, et al.: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499–511.
Bogaty P, Brophy JM, Boyer L, et al.: Fluctuating inflammatory markers in patients with stable ischemic heart disease. Arch Intern Med 2005, 165:221–226.
Pasceri V, Willerson JT, Yeh ET: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000, 102:2165–2168.
Pasceri V, Cheng JS, Willerson JT, Yeh ET: Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001, 103:2531–2534.
Devaraj S, Kumaresan PR, Jialal I: Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. J Mol Cell Cardiol 2004, 36:405–410.
Devaraj S, Xu DY, Jialal I: C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 2003, 107:398–404.
Singh U, Devaraj S, Jialal I: C-reactive protein decreases tissue plasminogen activator activity in human aortic endothelial cells. evidence that c-reactive protein is a procoagulant. Arterioscler Thromb Vasc Biol 2005, In press.
Venugopal SK, Devaraj S, Jialal I: C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation 2003, 108:1676–1678.
Venugopal SK, Devaraj S, Yuhanna I, et al.: Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002, 106:1439–1441.
Verma S, Wang CH, Li SH, et al.: A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002, 106:913–919.
Clapp BR, Hirschfield GM, Storry C, et al.: Inflammation and endothelial function: direct vascular effects of human C-reactive protein on nitric oxide bioavailability. Circulation 2005, 111:1530–1536.
Pepys MB: CRP or not CRP? That is the question. Arterioscler Thromb Vasc Biol 2005, 25:1091–1094.
Hirschfield GM, Gallimore JR, Kahan MC, et al.: Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A 2005, 102:8309–8314.
Trion A, de Maat MP, Jukema JW, et al.: No effect of C-reactive protein on early atherosclerosis development in apolipoprotein E*3-leiden/human C-reactive protein transgenic mice. Arterioscler Thromb Vasc Biol 2005, 25:1635–1640.
Reifenberg K, Lehr HA, Baskal D, et al.: Role of C-reactive protein in atherogenesis: can the apolipoprotein E knockout mouse provide the answer? Arterioscler Thromb Vasc Biol 2005, 25:1641–1646.
Uhlar CM, Whitehead AS: Serum amyloid A, the major vertebrate acute-phase reactant. Eur J Biochem 1999, 265:501–523.
Meek RL, Urieli-Shoval S, Benditt EP: Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. Proc Natl Acad Sci U S A 1994, 91:3186–3190.
Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836–843.
Jousilahti P, Salomaa V, Rasi V, et al.: The association of c-reactive protein, serum amyloid a and fibrinogen with prevalent coronary heart disease—baseline findings of the PAIS project. Atherosclerosis 2001, 156:451–456.
Ebeling P, Teppo AM, Koistinen HA, et al.: Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes. Diabetologia 1999, 42:1433–1438.
Haffner SM, Agostino RD Jr, Saad MF, et al.: Carotid artery atherosclerosis in type-2 diabetic and nondiabetic subjects with and without symptomatic coronary artery disease (The Insulin Resistance Atherosclerosis Study). Am J Cardiol 2000, 85:1395–1400.
Liao F, Andalibi A, deBeer FC, et al.: Genetic control of inflammatory gene induction and NF-kappa B-like transcription factor activation in response to an atherogenic diet in mice. J Clin Invest 1993, 91:2572–2579.
O’Brien KD, McDonald TO, Kunjathoor V, et al.: Serum amyloid A and lipoprotein retention in murine models of atherosclerosis. Arterioscler Thromb Vasc Biol 2005, In press.
Lewis KE, Kirk EA, McDonald TO, et al.: Increase in serum amyloid a evoked by dietary cholesterol is associated with increased atherosclerosis in mice. Circulation 2004, 110:540–545.
Poitou C, Viguerie N, Cancello R, et al.: Serum amyloid A: production by human white adipocyte and regulation by obesity and nutrition. Diabetologia 2005, 48:519–528.
Sjoholm K, Palming J, Olofsson LE, et al.: A microarray search for genes predominantly expressed in human omental adipocytes: adipose tissue as a major production site of serum amyloid A. J Clin Endocrinol Metab 2005, 90:2233–2239.
Miettinen TA, Kesaniemi YA: Cholesterol absorption: regulation of cholesterol synthesis and elimination and within-population variations of serum cholesterol levels. Am J Clin Nutr 1989, 49:629–635.
Simonen P, Gylling H, Howard AN, Miettinen TA: Introducing a new component of the metabolic syndrome: low cholesterol absorption. Am J Clin Nutr 2000, 72:82–88.
Weisberg SP, McCann D, Desai M, et al.: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796–1808.
Xu H, Barnes GT, Yang Q, et al.: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 112:1821–1830.
Kisilevsky R, Subrahmanyan L: Serum amyloid A changes high density lipoprotein’s cellular affinity. A clue to serum amyloid A’s principal function [published erratum appears in Lab Invest 1992 Jul;67(1):151]. Lab Invest 1992, 66:778–785.
Hayat S, Raynes JG: Acute phase serum amyloid A protein increases high density lipoprotein binding to human peripheral blood mononuclear cells and an endothelial cell line. Scand J Immunol 2000, 51:141–146.
Artl A, Marsche G, Lestavel S, et al.: Role of serum amyloid A during metabolism of acute-phase HDL by macrophages. Arterioscler Thromb Vasc Biol 2000, 20:763–772.
Migita K, Kawabe Y, Tominaga M, et al.: Serum amyloid A protein induces production of matrix metalloproteinases by human synovial fibroblasts. Lab Invest 1998, 78:535–539.
Strissel KJ, Girard MT, West-Mays JA, et al.: Role of serum amyloid A as an intermediate in the IL-1 and PMA-stimulated signaling pathways regulating expression of rabbit fibroblast collagenase. Exp Cell Res 1997, 237:275–287.
Badolato R, Wang JM, Murphy WJ, et al.: Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J Exp Med 1994, 180:203–209.
Xu L, Badolato R, Murphy WJ, et al.: A novel biologic function of serum amyloid A. Induction of T lymphocyte migration and adhesion. J Immunol 1995, 155:1184–1190.
Husebekk A, Skogen B, Husby G: Characterization of amyloid proteins AA and SAA as apolipoproteins of high density lipoprotein (HDL). Displacement of SAA from the HDL-SAA complex by apo AI and apo AII. Scand J Immunol 1987, 25:375–381.
Tam SP, Flexman A, Hulme J, Kisilevsky R: Promoting export of macrophage cholesterol: the physiological role of a major acute-phase protein, serum amyloid A 2.1. J Lipid Res 2002, 43:1410–1420.
Ancsin JB, Kisilevsky R: The heparin/heparan sulfate-binding site on apo-serum amyloid A. Implications for the therapeutic intervention of amyloidosis. J Biol Chem 1999, 274:7172–7181.
Kunjathoor VV, Chiu DS, O’Brien KD, LeBoeuf RC: Accumulation of biglycan and perlecan, but not versican, in lesions of murine models of atherosclerosis. Arterioscler Thromb Vasc Biol 2002, 22:462–468.
O’Brien KD, Olin KL, Alpers CE, et al.: Comparison of apolipoprotein and proteoglycan deposits in human coronary atherosclerotic plaques: colocalization of biglycan with apolipoproteins. Circulation 1998, 98:519–527.
Pennathur S, Bergt C, Shao B, et al.: Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species. J Biol Chem 2004, 279:42977–42983.
Bergt C, Pennathur S, Fu X, et al.: The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci U S A 2004, 101:13032–13037.
Shao B, Fu X, McDonald TO, et al.: Acrolein impairs ABCA1-dependent cholesterol export from cells through site-specific modification of apolipoprotein A-I. J Biol Chem 2005, In press.
Kinlay S, Schwartz GG, Olsson AG, et al.: High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation 2003, 108:1560–1566.
Schillinger M, Exner M, Mlekusch W, et al.: Statin therapy improves cardiovascular outcome of patients with peripheral artery disease. Eur Heart J 2004, 25:742–748.
Marx N, Froehlich J, Siam L, et al.: Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003, 23:283–288.
Skalen K, Gustafsson M, Rydberg EK, et al.: Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002, 417:750–754.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
O’Brien, K.D., Chait, A. Serum amyloid A: The “other” inflammatory protein. Curr Atheroscler Rep 8, 62–68 (2006). https://doi.org/10.1007/s11883-006-0066-0
Issue Date:
DOI: https://doi.org/10.1007/s11883-006-0066-0